No Data
No Data
Morgan Stanley Maintains Galapagos(GLPG.US) With Hold Rating, Maintains Target Price $35
Morgan Stanley analyst Judah Frommer maintains $Galapagos(GLPG.US)$ with a hold rating, and maintains the target price at $35.According to TipRanks data, the analyst has a success rate of 0.0% and a t
TD Cowen Maintains Galapagos(GLPG.US) With Buy Rating
TD Cowen analyst Phil Nadeau maintains $Galapagos(GLPG.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 0.0% and a total average return of 0.0% over the past year.N
Galapagos Says Cancer Treatment Showed High Response Rate in Trial
By Ben Glickman Galapagos said its potential cancer treatment had shown high complete response rates in a clinical trial. The Belgian pharmaceutical company said Friday that GLPG5101, its T-cell can
Express News | Galapagos To Present Data On CD19 CAR-T Candidate GLPG5101 For Relapsed/Refractory Non-Hodgkin Lymphoma At EHA 2024
Galapagos Presents Encouraging New Data for CD19 CAR-T Candidate GLPG5101 in Non-Hodgkin Lymphoma at EHA 2024
Mechelen, Belgium; June 14, 2024, 22:01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced that it will present encouraging new data from the ongoing Phase 1/2 ATALANTA-1 study of CD19 CAR-T candidate,
Retail Investors Are Galapagos NV's (AMS:GLPG) Biggest Owners and Were Hit After Market Cap Dropped €74m
whqqq : Thank you for your comprehensive sharing![undefined undefined](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36)